Novo Nordisk faces legal challenges on multiple fronts. A lawsuit regarding CagriSema results from December 2024 proceeds, and Novo sued Lilly on July 21 over "deceptive" GLP-1 ads. Meanwhile, Novo's endorsement of LifeMD is questioned by ex-worker testimony from July 20, and Wegovy's UK availability from July 6 awaits NICE approval.